Big Pharma's Top 5 Emerging Market Deals

With pharmaceutical sales in major markets like the United States, Europe and Japan slowing, a number of big drugmakers have looked outside of traditional territories to emerging markets. Eastern Europe, Russia, South America, the Middle East and Asia have all become sought-after markets as Big Pharma begins its emerging markets land-grab.

Below are the top five emerging market deals in the last 12 months. GlaxoSmithKline, which has been particularly aggressive about making deals in foreign markets, has three of our top five deals. But Abbott's $3.7 billion deal for India's Priamal takes the top spot. Click here to see the details. Report >>

1. Abbott and Piramal
2. GSK and Laboratorios Phoenix
3. Novartis and Zhejiang Tianyuan
4. GSK and Amgen
5. GSK and Dong-A

Erica Teichert also contributed to this report.

Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.